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Basic Research on Myocarditis
Superb But Unrequited*
Jay W. Mason, MD
Salt Lake City, Utah
Considerable progress has been made at the basic research
level in our understanding of the molecular pathophysiology
of myocarditis, as exempliﬁed by the eloquent report of
Weithauser et al. (1) in this issue of the Journal.
But, at the clinical level, myocarditis has been strikingly
resistant to successful scientiﬁc inquiry, as witnessed by the
absence of substantial improvements in its treatment. Why
the lack of translation?
See page 1737
Weithauser et al. (1) examined the role of protease-
activated receptor-2 (PAR2) in the pathogenesis of viral
myocarditis in a murine model exposed to coxsackievirus
B3 (CVB3). They observed a stunning reduction of viral
load and myocardial inﬂammation and improved survival in
PAR2-deﬁcient mice. Relevance of the observation to clin-
ical myocarditis was suggested by a correlation in patients
between PAR2 expression and the severity of myocardial
inﬂammation in biopsy specimens. The investigators con-
cluded by pointing to the therapeutic potential of PAR2
antagonism in myocarditis. Can this potential be met?
Before clinicians knew the basic pathophysiology of viral
myocarditis 60 years ago, immunosuppression was recom-
mended and used (2). Today, it is not formally accepted in
current treatment guidelines: International expert consensus
today only endorses nonspeciﬁc treatment of heart failure in
patients with known or suspected viral myocarditis (3).
Indeed, outside of the investigational setting, there are
simply no new generally accepted treatments of myocarditis,
and immunosuppression is often used by default. Even the
novel observations by Weithauser et al. (1) may have limited
therapeutic potential, because patients with viral myocarditis
infrequently present early enough in the disease process for
an antiviral treatment to be effective.*Editorials published in the Journal of the American College of Cardiology reﬂect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Department of Medicine, Cardiology Division, University of Utah, Salt
Lake City, Utah. Dr. Mason has reported that he has no relationships relevant to the
contents of this paper to disclose.Paradoxically, one source of translational disappointment
is the richness of choices available to the basic investigator.
The investigators used a Nancy strain of CVB3 virus to
induce myocarditis. This strain is highly myocarditic, but it is
also phenotypically diverse (4,5). It is not the only CVB3 virus
strain that could be used for inducing experimental myocar-
ditis, and it is only one of many viral species used to study
myocarditis. Added to this viral diversity are the assorted and
complex determinants of susceptibility of speciﬁc viral strains
to putative antiviral therapies (6). How can investigators know
if their speciﬁc virus-induced disease mimics any form of the
disease in humans and if it portrays responses to therapy that
could be expected in the clinical setting? Which is the right
viral strain for discovery of effective treatment?
Weithauser et al. (1) used C57BL/6 mice. This is the most
widely used mouse strain for genetic modiﬁcation (7), but
certainly not the only one that could have been used. What is
the right mouse strain for the study of viral myocarditis?
There are numerous other animal species that basic
investigators have employed to model myocarditis: rat (8);
guinea pig (9); hamster (10); rabbit (11); dog (12); pig (13);
and monkey (14). Some of these species, especially mice,
may be distinctively different in their susceptibility to the
effects of steroids (15) and other treatments. Which is the
right animal species for mimicking the human disease?
The quest for a therapeutic breakthrough in the treatment
of viral myocarditis is further hampered because the disease
itself is protean (16), progressing through an initial phase of
viral injury, then a period of autoimmune myocardial damage,
and ﬁnally a phase of adverse remodeling, in which infection,
immunity, and autoimmunity may no longer be relevant. This
variability complicates the effort to treat myocarditis because
the disease phases may overlap or repeat. As a result, new
therapies derived from the bench may not get a fair test at the
bedside. And, a very basic question is raised: Which phase of
the disease is the right therapeutic target?
Even in the scientiﬁcally more tractable animal model,
mechanistic complexity obscures the path to successful therapy.
In their current paper, Weithauser et al. (1) contend that the
improvement in myocarditis observed in PAR2-deﬁcient mice
is mediated through interferon and Toll-like receptor 3 path-
ways. Yet, the same Charité group had previously proposed
that the effect was a result of inhibition of myocardial ex-
pression of the coxsackie-adenovirus receptor. Whereas the
evidence presented in favor of the new explanation is strong,
and, the investigators are commended for re-examining and
revising their previous postulate, the main point is that most
relevant receptors presentmore than one potential downstream
therapeutic target. Which is the right therapeutic target?
What are the answers to the numerous questions posed
here? What is the solution to the failure of translation from
cell to beside in the case of myocarditis?
In fact, the investigators nicely illustrate one promising part
of the solution in this, as well as their previous work. They
avoided examining molecular mechanisms in an experimental
vacuum; rather, they combined their basic ﬁndings with
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paradigm for investigation of a disease such as myocarditis that
is poorly characterized clinically.
I see an opportunity to improve translation through
a renewed effort to characterize the clinical disorder. The cart
has gotten in front of the horse. We need to step back and
carry out a large, multinational observational study so that the
superb basic science we already have can be translated and can
become more informed by reverse translation. This sugges-
tion may seem backward, simplistic, uninteresting, and te-
dious. But, in most cases, clinicians managing patients with
myocarditis do not know what they are dealing with. Myo-
carditis is most often a presumptive diagnosis, and even if an
endomyocardial biopsy is done, there is considerable argu-
ment over diagnostic criteria, nomatter how sophisticated the
histological and molecular probes that are applied. Diagno-
sis aside, our inability to conﬁdently identify individual or
overlapping phases of the disease is a crippling deﬁciency that
must be corrected before science and clinical care can come
together.
The proposed observational study might enroll 1,000
patients to be followed for 3 years. Each would undergo the
most astute clinical observation, endomyocardial biopsy, and
magnetic resonance imaging, serially. The most promising
analyses would be applied to the tissue and blood samples,
and outcomes would be systematically documented. Therapy
would not be directed but would be carefully monitored.
Analysis of the data might help to answer many of the
questions posed here and break the block between bench and
bedside. Cost? About $10M.Reprint requests and correspondence: Dr. Jay W. Mason,
Medicine/Cardiology, University of Utah, 105 Londonderry Court,
Reno, Nevada 89511. E-mail: jmason12@charter.net.
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